Clearline Capital LP Lowers Position in Henry Schein, Inc. $HSIC

Clearline Capital LP lessened its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 12.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 205,566 shares of the company’s stock after selling 30,413 shares during the period. Henry Schein makes up about 0.8% of Clearline Capital LP’s investment portfolio, making the stock its 27th largest holding. Clearline Capital LP’s holdings in Henry Schein were worth $15,537,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HSIC. Ameriprise Financial Inc. increased its position in Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock valued at $165,594,000 after buying an additional 2,199,695 shares in the last quarter. Bank of Montreal Can increased its position in Henry Schein by 3,655.7% during the 4th quarter. Bank of Montreal Can now owns 2,144,773 shares of the company’s stock valued at $162,102,000 after buying an additional 2,087,666 shares in the last quarter. Norges Bank bought a new position in Henry Schein during the 4th quarter valued at approximately $88,116,000. Southpoint Capital Advisors LP increased its position in Henry Schein by 38.9% during the 4th quarter. Southpoint Capital Advisors LP now owns 2,500,000 shares of the company’s stock valued at $188,950,000 after buying an additional 700,000 shares in the last quarter. Finally, Bank of America Corp DE increased its position in Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock valued at $72,712,000 after buying an additional 668,182 shares in the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Down 1.5%

Henry Schein stock opened at $79.97 on Thursday. The firm has a market cap of $9.11 billion, a price-to-earnings ratio of 24.16, a PEG ratio of 1.57 and a beta of 0.82. The stock has a fifty day simple moving average of $75.75 and a two-hundred day simple moving average of $76.34. Henry Schein, Inc. has a 12 month low of $61.94 and a 12 month high of $89.29. The company has a current ratio of 1.36, a quick ratio of 0.75 and a debt-to-equity ratio of 0.59.

Henry Schein (NASDAQ:HSIC) last posted its earnings results on Tuesday, May 5th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.12. The business had revenue of $3.37 billion during the quarter, compared to analyst estimates of $3.34 billion. Henry Schein had a return on equity of 15.44% and a net margin of 2.95%.The company’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the company earned $1.15 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts predict that Henry Schein, Inc. will post 5.32 EPS for the current fiscal year.

Insider Activity at Henry Schein

In other news, Director William K. Daniel acquired 10,000 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was bought at an average price of $69.19 per share, with a total value of $691,900.00. Following the completion of the acquisition, the director directly owned 20,000 shares of the company’s stock, valued at approximately $1,383,800. The trade was a 100.00% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.89% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. BTIG Research raised Henry Schein from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a research report on Thursday, June 11th. UBS Group reaffirmed a “neutral” rating and set a $85.00 price objective (down from $87.00) on shares of Henry Schein in a research report on Wednesday, May 6th. Mizuho reduced their price objective on Henry Schein from $88.00 to $82.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. JPMorgan Chase & Co. raised their price objective on Henry Schein from $78.00 to $92.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, Robert W. Baird set a $97.00 price objective on Henry Schein in a research report on Wednesday, May 6th. Seven analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Henry Schein presently has an average rating of “Hold” and an average target price of $87.85.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.